|
||
Date of Report (Date of earliest event reported)
|
|
||
(Exact name of registrant as specified in its charter)
|
|
|
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
||
(Address of principal executive offices and zip code)
|
(
|
||
(Registrant’s telephone number, including area code)
|
N/A
|
||
(Former name or former address, if changed since last report)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Nu Skin Enterprises’ press release dated August 4, 2022, regarding financial results for the three- and six-month periods ended June 30, 2022.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
NU SKIN ENTERPRISES, INC. | |
|
(Registrant)
|
|
|
/s/ Mark H. Lawrence
|
|
|
Mark H. Lawrence
|
|
|
Chief Financial Officer
|
|
Date: August 4, 2022
|
|
Revenue:
|
$560.6 million; (20)%
• (5)% FX impact or $(34.6) million
|
||
Earnings Per Share (EPS):
|
$0.67 or $0.77 excluding charges associated with our Q4 2021 exit from Grow Tech, compared to $1.15 in Q2 2021
|
||
Customers:
|
1,380,615; (6)%
|
||
Paid Affiliates:
|
242,133; (16)%
|
||
Sales Leaders:
|
50,085; (24)%
|
•
|
Introduction of EmpowerMe, our personalized beauty and wellness strategy, with the launch of our connected LumiSpa iO device beginning in the third quarter;
|
•
|
Expansion of affiliate-powered social commerce by introducing a new affiliate incentive structure known as ‘One Price’ beginning with LumiSpa iO and other select products; and
|
•
|
Further adoption of our recently introduced Vera and Stela apps with expanded languages and functionality, as well as the introduction of MyShop in China.
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 2
|
Revenue:
|
$560.6 million compared to $704.1 million
• (5)% FX impact
|
||
Gross Margin:
|
73.6% compared to 75.6%
• Impacted by product mix and foreign currency exchange
• Nu Skin business was 77.0% compared to 78.3%
|
||
Selling Expenses:
|
39.1% compared to 39.9%
• Nu Skin business was 42.0% compared to 42.8%
|
||
G&A Expenses:
|
25.3% compared to 23.6%
|
||
Operating Margin:
|
9.2% compared to 12.1%
|
||
Other Income / (Expense):
|
$(8.6) million or $(2.9) million excluding charges associated with our Q4 2021 exit from Grow Tech, compared to $(4.0) million
|
||
Income Tax Rate:
|
20.2% compared to 27.1%
|
||
EPS:
|
$0.67 or $0.77 excluding charges associated with our Q4 2021 exit from Grow Tech, compared to $1.15 in Q2 2021
|
Dividend Payments:
|
$19.4 million
|
||
Stock Repurchases:
|
$10.0 million
• $225.4 million remaining in authorization
|
Q3 2022 Revenue:
|
$550 to $590 million; (13) to (8)%
• Approximately (6)% FX impact
|
||
Q3 2022 EPS:
|
$0.04 to $0.22 or $0.70 to $0.85 non-GAAP
|
||
2022 Revenue:
|
$2.33 to $2.41 billion; (14) to (11)%
• Approximately (5)% FX impact
|
||
2022 EPS:
|
$2.46 to $2.76 or $3.30 to $3.60 non-GAAP
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 3
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 4
|
•
|
risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;
|
•
|
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
•
|
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted
or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased
scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
|
•
|
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and
selling activities on a sustained basis;
|
•
|
political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
|
•
|
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland
China on our business operations and results;
|
•
|
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
•
|
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
•
|
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and
increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
|
•
|
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue
selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
|
•
|
unpredictable economic conditions and events globally, including trade policies and tariffs;
|
•
|
the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s
markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and
|
•
|
continued competitive pressures in the company’s markets.
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 5
|
Three Months Ended
June 30,
|
Change
|
Constant-
Currency
Change
|
||||||||||||||
2022
|
2021
|
|||||||||||||||
Nu Skin
|
||||||||||||||||
Americas
|
$
|
124,445
|
$
|
138,512
|
(10
|
)%
|
(9
|
)%
|
||||||||
Mainland China
|
86,808
|
154,182
|
(44
|
)%
|
(42
|
)%
|
||||||||||
Southeast Asia/Pacific
|
94,067
|
83,968
|
12
|
%
|
16
|
%
|
||||||||||
South Korea
|
69,308
|
88,604
|
(22
|
)%
|
(12
|
)%
|
||||||||||
Japan
|
55,952
|
68,020
|
(18
|
)%
|
(3
|
)%
|
||||||||||
EMEA
|
50,871
|
83,115
|
(39
|
)%
|
(31
|
)%
|
||||||||||
Hong Kong/Taiwan
|
39,327
|
38,529
|
2
|
%
|
6
|
%
|
||||||||||
Nu Skin other
|
1,318
|
947
|
39
|
%
|
39
|
%
|
||||||||||
Total Nu Skin
|
522,096
|
655,877
|
(20
|
)%
|
(15
|
)%
|
||||||||||
Rhyz Investments
|
||||||||||||||||
Manufacturing
|
38,229
|
48,140
|
(21
|
)%
|
(21
|
)%
|
||||||||||
Rhyz other
|
290
|
38
|
663
|
%
|
663
|
%
|
||||||||||
Total Rhyz Investments
|
38,519
|
48,178
|
(20
|
)%
|
(20
|
)%
|
||||||||||
Total
|
$
|
560,615
|
$
|
704,055
|
(20
|
)%
|
(15
|
)%
|
Six Months Ended
June 30,
|
Change
|
Constant-
Currency
Change
|
||||||||||||||
2022
|
2021
|
|||||||||||||||
Nu Skin
|
||||||||||||||||
Americas
|
$
|
248,025
|
$
|
272,273
|
(9
|
)%
|
(8
|
)%
|
||||||||
Mainland China
|
211,303
|
303,775
|
(30
|
)%
|
(31
|
)%
|
||||||||||
Southeast Asia/Pacific
|
184,303
|
167,257
|
10
|
%
|
14
|
%
|
||||||||||
South Korea
|
141,441
|
169,735
|
(17
|
)%
|
(8
|
)%
|
||||||||||
Japan
|
117,743
|
137,884
|
(15
|
)%
|
(3
|
)%
|
||||||||||
EMEA
|
103,839
|
159,295
|
(35
|
)%
|
(28
|
)%
|
||||||||||
Hong Kong/Taiwan
|
77,821
|
74,874
|
4
|
%
|
6
|
%
|
||||||||||
Nu Skin other
|
1,938
|
1,825
|
6
|
%
|
6
|
%
|
||||||||||
Total Nu Skin
|
1,086,413
|
1,286,918
|
(16
|
)%
|
(12
|
)%
|
||||||||||
Rhyz Investments
|
||||||||||||||||
Manufacturing
|
78,570
|
94,125
|
(17
|
)%
|
(17
|
)%
|
||||||||||
Rhyz other
|
531
|
38
|
1,297
|
%
|
1,297
|
%
|
||||||||||
Total Rhyz Investments
|
79,101
|
94,163
|
(16
|
)%
|
(16
|
)%
|
||||||||||
Total
|
$
|
1,165,514
|
$
|
1,381,081
|
(16
|
)%
|
(12
|
)%
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 6
|
Three Months Ended
June 30,
|
Change
|
|||||||||||
Customers
|
2022
|
2021
|
||||||||||
Americas
|
302,849
|
368,052
|
(18
|
)%
|
||||||||
Mainland China
|
$
|
392,268
|
328,526
|
19
|
%
|
|||||||
Southeast Asia/Pacific
|
152,775
|
165,221
|
(8
|
)%
|
||||||||
South Korea
|
135,290
|
153,282
|
(12
|
)%
|
||||||||
Japan
|
122,643
|
125,734
|
(2
|
)%
|
||||||||
EMEA
|
205,379
|
261,881
|
(22
|
)%
|
||||||||
Hong Kong/Taiwan
|
69,411
|
64,861
|
7
|
%
|
||||||||
Total
|
1,380,615
|
1,467,557
|
(6
|
)%
|
Three Months Ended
June 30,
|
Change
|
|||||||||||
Paid Affiliates
|
2022
|
2021
|
||||||||||
Americas
|
44,523
|
53,492
|
(17
|
)%
|
||||||||
Mainland China
|
$
|
19,257
|
39,889
|
(52
|
)%
|
|||||||
Southeast Asia/Pacific
|
41,512
|
44,734
|
(7
|
)%
|
||||||||
South Korea
|
48,605
|
52,680
|
(8
|
)%
|
||||||||
Japan
|
38,269
|
38,623
|
(1
|
)%
|
||||||||
EMEA
|
32,323
|
42,682
|
(24
|
)%
|
||||||||
Hong Kong/Taiwan
|
17,644
|
17,815
|
(1
|
)%
|
||||||||
Total
|
242,133
|
289,915
|
(16
|
)%
|
Three Months Ended
June 30,
|
Change
|
|||||||||||
Sales Leaders
|
2022
|
2021
|
||||||||||
Americas
|
9,320
|
11,752
|
(21
|
)%
|
||||||||
Mainland China
|
$
|
11,458
|
20,946
|
(45
|
)%
|
|||||||
Southeast Asia/Pacific
|
8,407
|
8,190
|
3
|
%
|
||||||||
South Korea
|
6,557
|
7,701
|
(15
|
)%
|
||||||||
Japan
|
6,097
|
6,057
|
1
|
%
|
||||||||
EMEA
|
5,192
|
8,002
|
(35
|
)%
|
||||||||
Hong Kong/Taiwan
|
3,054
|
3,446
|
(11
|
)%
|
||||||||
Total
|
50,085
|
66,094
|
(24
|
)%
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 7
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
Revenue
|
$
|
560,615
|
$
|
704,055
|
$
|
1,165,514
|
$
|
1,381,081
|
||||||||
Cost of sales
|
148,100
|
171,975
|
309,599
|
342,541
|
||||||||||||
Gross profit
|
412,515
|
532,080
|
855,915
|
1,038,540
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Selling expenses
|
219,426
|
280,589
|
462,125
|
556,554
|
||||||||||||
General and administrative expenses
|
141,562
|
166,115
|
290,118
|
333,697
|
||||||||||||
Total operating expenses
|
360,988
|
446,704
|
752,243
|
890,251
|
||||||||||||
Operating income
|
51,527
|
85,376
|
103,672
|
148,289
|
||||||||||||
Other income (expense), net
|
(8,640
|
)
|
(4,012
|
)
|
(10,093
|
)
|
(2,430
|
)
|
||||||||
Income before provision for income taxes
|
42,887
|
81,364
|
93,579
|
145,859
|
||||||||||||
Provision for income taxes
|
8,650
|
22,026
|
20,626
|
39,091
|
||||||||||||
Net income
|
$
|
34,237
|
$
|
59,338
|
$
|
72,953
|
$
|
106,768
|
||||||||
Net income per share:
|
||||||||||||||||
Basic
|
$
|
0.68
|
$
|
1.18
|
$
|
1.45
|
$
|
2.12
|
||||||||
Diluted
|
$
|
0.67
|
$
|
1.15
|
$
|
1.43
|
$
|
2.06
|
||||||||
Weighted-average common shares outstanding (000s):
|
||||||||||||||||
Basic
|
50,368
|
50,115
|
50,181
|
50,409
|
||||||||||||
Diluted
|
50,960
|
51,557
|
50,959
|
51,850
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 8
|
June 30,
2022
|
December 31,
2021
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
363,923
|
$
|
339,593
|
||||
Current investments
|
17,877
|
15,221
|
||||||
Accounts receivable, net
|
43,694
|
41,299
|
||||||
Inventories, net
|
354,211
|
399,931
|
||||||
Prepaid expenses and other
|
103,188
|
76,906
|
||||||
Total current assets
|
882,893
|
872,950
|
||||||
Property and equipment, net
|
443,036
|
453,674
|
||||||
Operating lease right-of-use assets
|
118,413
|
120,973
|
||||||
Goodwill
|
206,432
|
206,432
|
||||||
Other intangible assets, net
|
72,665
|
76,991
|
||||||
Other assets
|
177,462
|
175,460
|
||||||
Total assets
|
$
|
1,900,901
|
$
|
1,906,480
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
55,013
|
$
|
49,993
|
||||
Accrued expenses
|
289,130
|
372,201
|
||||||
Current portion of long-term debt
|
40,000
|
107,500
|
||||||
Total current liabilities
|
384,143
|
529,694
|
||||||
Operating lease liabilities
|
90,156
|
88,759
|
||||||
Long-term debt
|
387,179
|
268,781
|
||||||
Other liabilities
|
98,388
|
106,474
|
||||||
Total liabilities
|
959,866
|
993,708
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity:
|
||||||||
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
|
91
|
91
|
||||||
Additional paid-in capital
|
606,349
|
601,703
|
||||||
Treasury stock, at cost – 39.9 million and 40.7 million shares
|
(1,520,769
|
)
|
(1,526,860
|
)
|
||||
Accumulated other comprehensive loss
|
(90,638
|
)
|
(73,896
|
)
|
||||
Retained earnings
|
1,946,002
|
1,911,734
|
||||||
Total stockholders' equity
|
941,035
|
912,772
|
||||||
Total liabilities and stockholders’ equity
|
$
|
1,900,901
|
$
|
1,906,480
|
Nu Skin Enterprises Reports Second Quarter Financial Results
|
page 9
|
Three Months Ended
June 30, 2022
|
||||
Net income
|
$
|
34,237
|
||
Impact of charges associated with our Q4 2021 exit from Grow Tech:
|
||||
Unrealized investment loss
|
5,711
|
|||
Income tax impact
|
(459
|
)
|
||
Adjusted net income
|
$
|
39,489
|
||
Diluted earnings per share
|
$
|
0.67
|
||
Diluted earnings per share, excluding charges associated with our Q4 2021 exit from Grow Tech
|
$
|
0.77
|
||
Weighted-average common shares outstanding (000s):
|
50,960
|
Three Months Ended
June 30, 2022
|
||||
Other income (expense), net
|
$
|
(8,640
|
)
|
|
Impact of charges associated with our Q4 2021 exit from Grow Tech:
|
||||
Unrealized investment loss
|
5,711
|
|||
Adjusted Other income (expense), net
|
$
|
(2,929
|
)
|
Three Months Ended
September 30, 2022
|
Year Ended
December 31, 2022
|
|||||||||||||||
Low End
|
High End
|
Low End
|
High End
|
|||||||||||||
Earnings per share
|
$
|
0.04
|
$
|
0.22
|
$
|
2.46
|
$
|
2.76
|
||||||||
Impact of charges associated with our second half restructuring and impairment charges:
|
||||||||||||||||
Restructuring and Impairment
|
0.59
|
0.59
|
0.88
|
0.88
|
||||||||||||
Income tax impact
|
0.07
|
0.04
|
(0.13
|
)
|
(0.13
|
)
|
||||||||||
Impact of charges associated with our Q4 2021 exit from Grow Tech:
|
||||||||||||||||
Unrealized investment loss
|
—
|
—
|
0.11
|
0.11
|
||||||||||||
Income tax impact
|
—
|
—
|
(0.02
|
)
|
(0.02
|
)
|
||||||||||
Adjusted Earnings per share
|
$
|
0.70
|
$
|
0.85
|
$
|
3.30
|
$
|
3.60
|